Business
/C O R R E C T I O N -- Harmony Biosciences/
In the news release, Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting, issued June 10,
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"text","content":"In the news release, Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting, issued June 10, 2021 by Harmony Biosciences over PR Newswire, we are advised by the company that the release has been updated. The complete, corrected release follows:\n\nHarmony Biosciences Presents New Analysis Demonstrating The Clinical Impact Of WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting\n\nData highlight the clinical effectiveness of WAKIX for excessive daytime sleepiness and cataplexy in adults with narcolepsy\n\n\nPLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (\"Harmony\") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat (NNT) and effect sizes for treatment with WAKIX® (pitolisant) that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The poster was presented at the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as \"SLEEP 2021,\" held virtually June 10-13. \n\n \n \n \n \n \n \n\n \nAssessment of the Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy \nThis poster presents results from a new analysis that evaluated the clinical impact of pitolisant in adults with narcolepsy using NNT and effect size as measures of treatment response based on data from the HARMONY 1 and HARMONY CTP randomized, controlled clinical trials. NNT and effect size are important metrics as they measure the number of patients that need to be treated to achieve a specific outcome for one person (NNT) and the magnitude of drug–placebo difference on outcome measures (effect size). NNT values less than 10 are considered to represent a clinically meaningful difference (with lower values equating to greater efficacy) and thresholds for effect size are 0.2 for a small effect, 0.5 for a medium effect, and 0.8 representing a large effect size, with larger effect sizes signifying greater efficacy. \nFor improvement in EDS, NNT was based on response defined as an Epworth Sleepiness Scale ...